Travoprost Ophthalmic Solution USP, 0.004%, a) 2.5 mL and b) 5 mL bottles, Rx only, FOR USE IN TH...
FDA Drug Recall #D-0154-2017 — Class II — October 5, 2016
Recall Summary
| Recall Number | D-0154-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 5, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Par Pharmaceutical, Inc. |
| Location | Chestnut Ridge, NY |
| Product Type | Drugs |
| Quantity | a) 182,856 bottles; b) 59,448 bottles |
Product Description
Travoprost Ophthalmic Solution USP, 0.004%, a) 2.5 mL and b) 5 mL bottles, Rx only, FOR USE IN THE EYES ONLY, Made in India, Distributed by: Par Pharmaceutical Cos., Inc, Spring Valley, NY 10977
Reason for Recall
Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container
Distribution Pattern
Nationwide
Lot / Code Information
a) G40814 - Exp. Date 09/2016, GA50089 - Exp. Date 12/2016, GA50259 - Exp. Date 01/2017, GA50657 - Exp. Date 03/2017, GA51073 - Exp. Date 06/2017, GA51651 - Exp. Date 09/2017, GA51652 - Exp. Date 09/2017, GA51722 - Exp. Date 09/2017, GA51723 - Exp. Date 09/2017, GA51760 - Exp. Date 10/2017, and GA51761 - Exp. Date 10/2017 b) GA45033 - Exp. Date 10/2016, GA50258 - Exp. Date 01/2017, GA50944 - Exp. Date 05/2017, GA50174 - Exp. Date 06/2017, GA51340 - Exp. Date 07/2017, GA51479 - Exp. Date 08/2017, and GA51762 - Exp. Date 10/2017
Other Recalls from Par Pharmaceutical, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1293-2019 | Class I | Mycophenolate Mofetil for Injection, USP 500 m... | Apr 30, 2019 |
| D-1185-2018 | Class III | Pramipexole dihydrochloride extended release ta... | Sep 6, 2018 |
| D-0121-2017 | Class III | Gildess FE 1/20 (norethindrone acetate, 1 mg an... | Sep 27, 2016 |
| D-0123-2017 | Class III | Gildess 24 FE 1.5/30 (norethindrone acetate, 1 ... | Sep 27, 2016 |
| D-0119-2017 | Class III | Gildess 1.5/30 (norethindrone acetate, 1.5 mg a... | Sep 27, 2016 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.